An FDA advisory panel moved to expand access to several unapproved peptides, in a politically charged vote that health secretary Robert F. Kennedy Jr. has linked to increased availability of compounded drugs. The Pharmacy Compounding Advisory Committee recommended allowing compounding of some peptides while narrowly rejecting others, setting up additional FDA review steps and potential policy fallout.